bladder urothelial carcinoma (Cancer)
Information
- Disease name
- bladder urothelial carcinoma
- Disease ID
- DOID:4006
- Description
- "A bladder carcinoma that has_material_basis_in transitional cells located_in the lining of the bladder." [url:http\://cancergenome.nih.gov/cancersselected/UrothelialBladderCarcinoma, url:http\://www.cancer.gov/dictionary?cdrid=46629]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04167631 | Active, not recruiting | N/A | Can VI-RADS/ADC Accurately Stage Bladder Cancer?? | January 1, 2019 | January 1, 2024 |
| NCT02496208 | Active, not recruiting | Phase 1 | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | July 22, 2015 | September 30, 2024 |
| NCT03039413 | Active, not recruiting | Early Phase 1 | Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy | September 28, 2016 | April 2024 |
| NCT04216290 | Active, not recruiting | Phase 2 | A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes (The INSPIRE Study) | March 17, 2021 | June 30, 2026 |
| NCT03473730 | Active, not recruiting | Early Phase 1 | Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer | May 29, 2018 | June 30, 2024 |
| NCT03601455 | Active, not recruiting | Phase 2 | Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer | October 26, 2018 | January 31, 2026 |
| NCT03775265 | Active, not recruiting | Phase 3 | Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer | June 3, 2019 | June 1, 2027 |
| NCT00238420 | Completed | Phase 1/Phase 2 | Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer | July 26, 2005 | May 20, 2022 |
| NCT03329950 | Completed | Phase 1 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | December 1, 2017 | September 13, 2022 |
| NCT02989064 | Completed | Phase 1 | MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | October 2016 | June 4, 2020 |
| NCT04200963 | Completed | Phase 1 | A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma | December 18, 2019 | July 18, 2023 |
| NCT04440943 | Completed | Phase 1 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | August 4, 2020 | April 6, 2023 |
| NCT06263153 | Not yet recruiting | Phase 2 | Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy | June 1, 2024 | December 31, 2025 |
| NCT06416319 | Recruiting | N/A | Preoperative Physical Activity Improvement With the Use of Activity Trackers Before Radical Cystectomy (PreAct) | March 14, 2023 | March 14, 2026 |
| NCT04570410 | Recruiting | Phase 2 | Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma | October 1, 2020 | December 1, 2024 |
| NCT04574960 | Recruiting | Phase 3 | Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL) | February 8, 2021 | December 2025 |
| NCT04985604 | Recruiting | Phase 1/Phase 2 | Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors | July 15, 2021 | December 31, 2025 |
| NCT05220124 | Recruiting | Phase 4 | A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma | January 5, 2022 | November 30, 2024 |
| NCT05296564 | Recruiting | Phase 1/Phase 2 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | April 1, 2022 | December 30, 2027 |
| NCT05669430 | Recruiting | Phase 1 | A Study of GV20-0251 in Patients With Solid Tumor Malignancies | March 23, 2023 | June 15, 2026 |
| NCT05788484 | Recruiting | Phase 1 | A Study of CDX-585 in Patients With Advanced Malignancies | May 11, 2023 | February 2026 |
| NCT05833997 | Recruiting | N/A | Safety Analysis and Oncological Outcomes in HoLERT vs TURBT | December 10, 2020 | December 2025 |
| NCT06167356 | Recruiting | Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK. | November 27, 2013 | November 27, 2063 | |
| NCT06170177 | Recruiting | Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy | February 4, 2013 | February 2063 | |
| NCT03266900 | Terminated | Early Phase 1 | A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival | November 16, 2017 | October 4, 2021 |
| NCT00072137 | Terminated | Phase 1 | Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy | October 2003 | November 2010 |
| NCT03912818 | Terminated | Phase 2 | Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer | April 10, 2019 | August 11, 2022 |
| NCT05052372 | Terminated | Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib | November 21, 2021 | December 20, 2022 | |
| NCT05012397 | Terminated | Phase 2 | Milademetan in Advanced/Metastatic Solid Tumors | November 1, 2021 | October 15, 2023 |
| NCT05027412 | Unknown status | N/A | En Bloc TURBT With Collins Loop vs Conventional TURBT | April 1, 2021 | June 2023 |
| NCT04129606 | Unknown status | N/A | Bladder Perforation Post-TURBT: Definition, Incidence and Natural HistoryStudy | July 1, 2019 | July 1, 2021 |
| NCT03138824 | Unknown status | N/A | Storz Professional Image Enhancement System Versus White Light Imaging Assisted TURBT for Treatment of NMIBC | May 15, 2017 | May 1, 2018 |
| NCT03113266 | Unknown status | Phase 2 | Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma | April 6, 2017 | February 2022 |
| NCT01968928 | Unknown status | The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma | January 2014 | December 2016 | |
| NCT05564416 | Withdrawn | Phase 2 | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial | October 12, 2023 | November 3, 2023 |
- Disase is a (Disease Ontology)
- DOID:4007
- Cross Reference ID (Disease Ontology)
- NCI:C39851
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:393562002
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0279680
- Exact Synonym (Disease Ontology)
- bladder transitional cell carcinoma
- Exact Synonym (Disease Ontology)
- transitional cell carcinoma of bladder
- Exact Synonym (Disease Ontology)
- urinary bladder urothelial carcinoma
- Exact Synonym (Disease Ontology)
- urothelial bladder carcinoma